mate, i'm not sure how seasoned i am but my view is - if the cpat trials work out well and quickly and the pills are on shelves for cats and dogs in the us and here in 2021 i feel there is no reason why cannpal wouldn't be a 100 mill company. conservatively because not even mentioning ip, future clinical trials and medicinal products in pipeline and nutraceutical/dermatological. with this tightly held share register, assuming small future dilution on 100 mill mc would leave us at about 80c and set for near term rapid growth after that. thats my dream, anyway, all imo. or alternatively the directors turn out to be shonks and the pills don't work and we'll be .08c lol. it's happened. GLALTH.
CP1 Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
